Meeting
2020 ASCO Virtual Scientific Program
RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Authors
Grzegorz S. Nowakowski
Division of Hematology, Mayo Clinic, Rochester, MN
Grzegorz S. Nowakowski , Thomas David Rodgers , Dario Marino , Maurizio Frezzato , Anna Maria Barbui , Claudia Castellino , Erika Meli , Nathan Hale Fowler , Bruce A. Feinberg , Sascha Tillmanns , Stephan Parche , Guenter Fingerle-Rowson , Mark Winderlich , Sumeet Vijay Ambarkhane , Gilles A. Salles , Pier Luigi Zinzani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04150328
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8020)
DOI
10.1200/JCO.2020.38.15_suppl.8020
Abstract #
8020
Poster Bd #
353
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
First Author: Johannes Düll
First Author: Jennifer Leigh Crombie
Poster
2022 ASCO Annual Meeting
inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
First Author: Laurie Helen Sehn
Poster
2022 ASCO Annual Meeting
frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.
First Author: Umberto Vitolo